{"id":27870,"date":"2014-08-11T10:36:32","date_gmt":"2014-08-11T14:36:32","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=27870"},"modified":"2014-08-11T10:36:32","modified_gmt":"2014-08-11T14:36:32","slug":"sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870","title":{"rendered":"Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/11\/2014 (wallstreetpr) \u2013 French drug company <b>Sanofi SA (ADR) (NYSE:SNY)<\/b> and <b>MannKind Corporation (NASDAQ:MNKD)<\/b> have entered a <a href=\"http:\/\/online.wsj.com\/article\/PR-CO-20140811-900182.html\">global collaboration<\/a> that involves developing and marketing of the inhaled insulin therapy, Afrezza, targeting adults with types 1 and 2 of diabetes. Afrezza is billed as rapid-acting inhaled insulin, a new solution for diabetes patients that the companies believe their joint efforts can help penetrate more markets and improve the lives of many more patients.<\/p>\n<p style=\"text-align: justify;\">Top on the agenda, the companies have promised to launch Afrezza in the U.S. in 1Q2015.<\/p>\n<p style=\"text-align: justify;\">On to other details of the agreement, Sanofi SA (ADR) (NYSE:SNY) and MannKind said in a statement that their agreement involves Sanofi taking over the responsibilities for global commerce, development activities and regulatory matters. However, MannKind Corporation (NASDAQ:MNKD) will on its part manufacture Afrezza. The statement went further to state that MannKind will do the manufacturing at its facility in Danbury, Connecticut.\u00a0 The agreement also involves plans by the companies to enhance the manufacturing capacity of Afrezza so as to meet the global demand for the therapy.<\/p>\n<p style=\"text-align: justify;\"><b>Payment involved<\/b><\/p>\n<p style=\"text-align: justify;\">The agreement states than Sanofi SA (ADR) (NYSE:SNY) will make payment of $150 million to MannKind in upfront consideration with up to $775 million in milestone payments. However, they said the milestone payments will depend upon meeting of certain regulatory and development targets. Furthermore, the company said they would share profits and losses in the collaboration such that Sanofi will retain 65 percent while MannKind will retain the rest \u2013 35 percent.<\/p>\n<p style=\"text-align: justify;\"><b>Praising the deal<\/b><\/p>\n<p style=\"text-align: justify;\">According to Pierre Chancel, a senior vice president at Sanofi SA (ADR) (NYSE:SNY), Affrezza becomes another important addition to their expanding portfolio of integrated solutions for diabetes. He further states that the therapy is uniquely placed to offer patients with another treatment option that doesn\u2019t require injections.<\/p>\n<p style=\"text-align: justify;\">On their part, MannKind\u2019s CEO Alfred Mann praised their collaboration with Sanofi SA (ADR) (NYSE:SNY) and for the opportunity to bring Afrezza to global diabetes patients. He also said Sanofi is an ideal partner by the virtue that their product portfolios complement.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/11\/2014 (wallstreetpr) \u2013 French drug company Sanofi SA (ADR) (NYSE:SNY) and MannKind Corporation (NASDAQ:MNKD) have entered a global collaboration that involves developing and [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":20649,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3395,2246,2247,3599,3600,3598],"stock_ticker":[],"class_list":["post-27870","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-mannkind-corporation","tag-mannkind-corporation-nasdaqmnkd","tag-nasdaqmnkd","tag-nysesny","tag-sanofi-sa-adr","tag-sanofi-sa-adr-nysesny","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/11\/2014 (wallstreetpr) \u2013 French drug company Sanofi SA (ADR) (NYSE:SNY) and MannKind Corporation (NASDAQ:MNKD) have entered a global collaboration that involves developing and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-11T14:36:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/Sanofi.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"347\" \/>\n\t<meta property=\"og:image:height\" content=\"145\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal\",\"datePublished\":\"2014-08-11T14:36:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/Sanofi.jpeg\",\"keywords\":[\"MannKind Corporation\",\"MannKind Corporation (NASDAQ:MNKD)\",\"NASDAQ:MNKD\",\"NYSE:SNY\",\"Sanofi SA (ADR)\",\"Sanofi SA (ADR) (NYSE:SNY)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870\",\"name\":\"Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/Sanofi.jpeg\",\"datePublished\":\"2014-08-11T14:36:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/Sanofi.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/Sanofi.jpeg\",\"width\":347,\"height\":145},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870","og_locale":"en_US","og_type":"article","og_title":"Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal - Wall Street PR","og_description":"Boston, MA 08\/11\/2014 (wallstreetpr) \u2013 French drug company Sanofi SA (ADR) (NYSE:SNY) and MannKind Corporation (NASDAQ:MNKD) have entered a global collaboration that involves developing and [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-11T14:36:32+00:00","og_image":[{"width":347,"height":145,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/Sanofi.jpeg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal","datePublished":"2014-08-11T14:36:32+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/Sanofi.jpeg","keywords":["MannKind Corporation","MannKind Corporation (NASDAQ:MNKD)","NASDAQ:MNKD","NYSE:SNY","Sanofi SA (ADR)","Sanofi SA (ADR) (NYSE:SNY)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870","url":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870","name":"Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/Sanofi.jpeg","datePublished":"2014-08-11T14:36:32+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/Sanofi.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/Sanofi.jpeg","width":347,"height":145},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/sanofi-sa-adr-nysesny-mannkind-nasdaqmnkd-in-afrezza-licensing-deal-27870#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/27870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=27870"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/27870\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/20649"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=27870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=27870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=27870"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=27870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}